Joel L. Syphers

Joel L. Syphers

Auto-generated profile, based on publicly available information

Joel L. Syphers

Monash University 381 Royal Parade

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JSJoel L. Syphers
Joel L. Syphers
JWJosephine A. Wright
Josephine A. Wright
SLShen Liu
Shen Liu
YGYi Sing Gee
Yi Sing Gee
FGFan Gao
Fan Gao
JBJonathan Bayldon Baell
Jonathan Bayldon Baell

6 April 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JSJoel L. Syphers
Joel L. Syphers
JWJosephine A. Wright
Josephine A. Wright
RNRebekah de Nys
Rebekah de Nys
TSTharindie Silva
Tharindie Silva
LVLaura Vrbanac
Laura Vrbanac
JBJonathan Bayldon Baell
Jonathan Bayldon Baell
Herein, we report the discovery of APO-50815 (14), a potent and selective thietane-3-ol WEE1 inhibitor. When tested against TP53-mutated colorectal cancer (CRC) patient-derived organoids (PDOs) grown from peritoneal and liver metastases, 14 exhibited outstanding anticancer efficacy, surpassing previously reported branched alkane counterpart 3, as well as clinical candidates AZD1775 (1) and ZN-c3 (2). Against primary CRC organoids with diverse TP53, BRAF and KRAS mutation profiles compared with patient-matched normal colon organoids, 14 exhibited selectively potent activity, yielding exceptionally high TI values (129-238) that highlight a substantial therapeutic window for potential cancer treatment. Against primary CRC PDOs (TP53-WT, BRAF-V600E, KRAS-WT), 14 profoundly elevated DNA damage and replication stress compared to 1, while amplifying cellular apoptosis, confirming a broadly similar but superior mode of action. Owing to its highly selective and exemplary anticancer efficacy, 14 represents a valuable tool compound for drug testing investigations against primary and metastatic CRCs, especially in the context of PDOs.

13 June 2023 in ACS Chemical Biology
Verified
Journal Article
Closed access
JSJoel L. Syphers
Joel L. Syphers
LXLian Xue
Lian Xue
XYXiangyan Yi
Xiangyan Yi
RWRongsheng E. Wang
Rongsheng E. Wang
BHBrad Haubrich
Brad Haubrich

19 August 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JSJoel L. Syphers
Joel L. Syphers
JWJosephine A. Wright
Josephine A. Wright
AKAdarsh Kumar
Adarsh Kumar
NTNikos To
Nikos To
LELewis Elson
Lewis Elson
JBJonathan Bayldon Baell
Jonathan Bayldon Baell
Macrocyclization can enhance the selectivity of acyclic compounds toward structurally similar biological targets such as kinases. WEE1 regulates cellular homeostasis and is a promising target in oncology. The clinical candidate AZD1775 (1) failed to progress past Phase II trials because of patient tolerability issues, likely due to off-target inhibition of polo-like kinase 1 (PLK1). Herein, a computer-aided drug design approach was conducted to develop a macrocycle based on the 1-WEE1 X-ray cocrystal structure. Significantly enhanced WEE1 inhibitory selectivity over PLK1 was determined for leading macrocycle 2, which also demonstrated broader kinome-wide selectivity. Patient-derived organoids from colorectal cancer (CRC) peritoneal and liver metastases, treated with 2, demonstrated comparably strong or enhanced anticancer efficacy compared to that of 1. Against patient-matched normal colon vs primary CRC organoids, 2 potently and selectively treated CRC, as well as enhanced DNA damage compared to 1. Finally, the X-ray cocrystal structure of 2 bound to WEE1 validated its computationally predicted bioactive binding mode.